June 25, 2019

The holy grail of the pharma industry is FDA approval, but the final clue may be positive top-line (Phase III) results.  However, it is not out of the question that a Phase III study can meet its efficacy endpoint, yet still be rejected by the FDA.  This may especially...

June 25, 2019

High-throughput screening (HTS) has been a blessing and a curse.  A blessing in codifying a straightforward approach to discovering drug candidates once a particular target has been identified.  But a curse in terms of its overall efficiency, with many extremely expens...

June 25, 2019

Where to even begin?  A mold flew in through the window and, presto, penicillin. Hey, then, why not screen all the compounds we have on the shelves in those bacterial/assay/etc dishes?  And so began screening for drug candidates.

But bigger quickly became assumed...

May 30, 2019

We waited a long time for a real gene therapy, though we were promised it would be easy. So now we are feeling optimistic about the other recalcitrant biomedical challenges. What about a first-in-class drug for schizophrenia?  Where are we with that?

Well, in the same o...

Please reload

THE GENE

EXPRESS

Recent News

Nucleic freeze

April 2, 2020

Surface charm

April 2, 2020

Target practice

April 2, 2020

1/4
Please reload

Tags